Preparation and preliminary biological evaluation of a novel 109Pd labeled porphyrin derivative for possible use in targeted tumor therapy

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 51, Issue 1, 2007, Pages 16-23

  Chakraborty, S ^a   Das, T ^a   Banerjee, Sharmila ^a   Sarma, H D ^a   Venkatesh, M ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

Neoplasms; Porphyrins; Radiopharmacology; Targeted radiotherapy

Indexed keywords

5,10,15,20 TETRAKIS[3,4 BIS(CARBOXYMETHYLENEOXY)PHENYL]PORPHYRIN PD 109; PALLADIUM; PALLADIUM 109; PROTOCATECHUALDEHYDE; PYRROLE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; CANCER THERAPY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TARGETING; FIBROSARCOMA; KIDNEY CLEARANCE; MOUSE; NEUTRON RADIATION; NONHUMAN; SWISS WEBSTER MOUSE; URINARY EXCRETION;

ANIMALS; FEASIBILITY STUDIES; FIBROSARCOMA; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; ORGAN SPECIFICITY; PALLADIUM; PORPHYRINS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 34249686996     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Pauwels EKJ, McCready VR, Stoot JHMB, van Deurzen DFP. Mechanism of accumulation of tumour-localising radiopharmaceuticals. Eur J Nucl Med 1998;25:277-305.
2. Jaracz S, Chen J, Kuznetsove LV, Ozima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 2005;13:5043-54.
3. Jurisson SS, Lydon JD. Potential technetium small molecule radiopharmaceuticals. Chem Rev 1999;99:2205-18.
4. Zalutsky MR. Radionuclide therapy. In: Vertes A, Nagy S, Klencsar Z, editors. Radiochemistry and radiopharmaceutical chemistry in life sciences. Amsterdam: Kluwer Academic Publishers; 2003.p.315-48.
5. Sanderson DR, Fontana RS, Lipson RL, Baldes EJ. Hematoporphyrin as a diagnostic tool. Cancer 1972;30:1368-72.
6. Fawwaz R, Bohdiewicz P, Lavallee D, Wang T, Oluwole S, Newhouse J et al. Use of metalloporphyrin in diagnostic imaging. Nucl Med Biol 1990;17:65-72.
7. Lipson RL, Baldes EJ, Gray MS. Hematoporphyrin derivative for detection and management of cancer. Cancer 1967;20:2255-7.
8. 186/188Rel-labeled porphyrin for targeted radiotherapy. Nucl Med Commun 2001;22:1101-7.
9. 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia. Bioorg Med Chem 2004;12:6077-84.
10. 177Lu labeled metronidazole for possible use in targeting tumor hypoxia. Radiochim Acta 2006;94:375-80.
11. 109Pd-porphyrin complexes for selective lymphatic abalation. J Nucl Med 1971;12:231-6.
12. 109Pd-protoporphyrin. J Nucl Med 1974;15:997-1002.
13. 109Pd-hematoporphyrin for selective lymphatic abalation using N-methylehematoporphyrin. Int J Appl Radiat Isot 1981;32:877-80.
14. Falk JE. Porphyrins and metalloporphyrins. New York: Elsevier Science Publishing Company; 1975.
15. Chen FM, Troutner DE. A bifunctional ligand for Pd(II). Int J Radiat Appl Instrum Part B Nucl Med Biol 1986;13:369-72.
16. Fawwaz RA, Wang TST, Srivastava SC, Rosen JM, Ferrone S, Hardy MA et al. Potential of palladium-109-labeled antimelanoma monoclonal antibody for tumor therapy. J Nucl Med 1984;25:796-9.
17. Firestone RB. Table of isotopes. New York: John Wiely and Sons Inc; 1996.
18. 99mTc labeled porphyrin for specific imaging of sarcoma 120: synthesis and biological study in a Swiss mouse model. J Label Compd Radiopham 1996;38:411-8.
19. 99mTc complexes of modified cysteine ligands and bifunctional chelating agents. Nucl Med Biol 1999; 26:555-61.